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Abstract
Heat shock factor 1 (HSF1) was discovered in 1984 as the master regulator of the heat shock 
response. In this classical role, HSF1 is activated following cellular stresses such as heat shock 
that ultimately lead to HSF1-mediated expression of heat shock proteins to protect the proteome 
and survive these acute stresses. However, it is now becoming clear that HSF1 also plays a 
significant role in several diseases, perhaps none more prominent than cancer. HSF1 appears to 
have a pleiotropic role in cancer by supporting multiple facets of malignancy including migration’ 
invasion, proliferation, and cancer cell metabolism among others. Because of these functions, and 
others, of HSF1, it has been investigated as a biomarker for patient outcomes in multiple cancer 
types. HSF1 expression alone was predictive for patient outcomes in multiple cancer types but in 
other instances, markers for HSF1 activity were more predictive. Clearly, further work is needed to 
tease out which markers are most representative of the tumor promoting effects of HSF1. 
Additionally, there have been several attempts at developing small molecule inhibitors to reduce 
HSF1 activity. All of these HSF1 inhibitors are still in preclinical models but have shown varying 
levels of efficacy at suppressing tumor growth. The growth of research related to HSF1 in cancer 
has been enormous over the last decade with many new functions of HSF1 discovered along the 
way. In order for these discoveries to reach clinical impact, further development of HSF1 as a 
biomarker or therapeutic target needs to be continued.
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1. INTRODUCTION
The heat shock response was initially discovered in 1962 [1] and subsequent studies 
identified heat shock factor 1 (HSF1) as the “master regulator” of the heat shock response 
[2, 3]. HSF1 is a helix-turn-helix transcription factor that binds to heat shock elements 
(HSEs) located in the promoters of target genes [4–7]. HSF1 is now increasingly being 
recognized to play a role in several diseases including cancer and neurodegenerative 
diseases. Complicating matters, HSF1 is overactive or overexpressed in many cancers but 
loses activity in neurodegenerative diseases leading to neuron death from the unfolded 
protein response.
HSF1 has now been recognized to play a role in many areas of tumor biology and has strong 
associations with patient outcomes. While the heat shock response has been associated with 
cancer for decades, the first mention of HSF1 having altered function in cancer was in 
prostate cancer [8]. Subsequently, HSF1 has been shown to have altered expression or 
function in colorectal [9], breast cancer [10–13], lymphomas [14, 15], hepatocellular 
carcinoma [16–20], oral cancers [21–23], melanoma [24, 25], pancreatic cancers [26–28], 
gynecologic cancers [29–32], and others [33–35].
2. HSF1 GENE AND PROTEIN STRUCTURE AND FUNCTION
There are six human HSF genes in HSF1–2, HSF4–5, HSFX-Y (Fig. 1A). HSF1 is, by far, 
the most understood of these isoforms. HSF2 has been linked to early development [36] and 
HSF4 is involved in eye lens development [37, 38]. The function of HSF5 and HSFX is 
currently unknown. HSFY has been linked to male fertility [39] and HSF3 has only been 
identified in mice but not humans [40]. HSF1 has been most closely linked with regulating 
the heat shock response aside from its role in tumor development and progression. The 
HSF1 gene is located on the long arm of chromosome 8 (8q24.3) that results in a gene of 
23,135 bp with 13 exons. The resulting 2,193 bp mRNA and 529 amino acid protein of 
HSF1 are constitutively expressed under physiological conditions (Fig. 1B). The mouse gene 
is located on chromosome 15 resulting in a protein with 553 residues [41]. The human and 
mouse HSF1 protein have 86% similarity. HSF1 is not frequently mutated in cancer but we 
have reported that the gene is amplified in 15°% of breast cancers resulting in increased 
mRNA expression [42]. Additionally, HSF1 mRNA is upregulated in 25% of breast cancers 
indicating that there are likely additional mechanisms driving increased expression of HSF 1 
in breast cancers aside from gene amplification [42].
The classical heat shock response involves HSF1 activation in response to cell stress. In 
healthy quiescent cells, HSF1 protein is kept in a folded, inactive state and in an inhibitory 
protein complex with Hsp90, Hsp70, Hsp40, and the TRiC/CCt complex [43–46]. This 
inhibitory complex is dissolved in response to a heat stress wherein the HSPs are shuttled 
toward cellular proteins to protect the integrity of the proteome [46, 47]. HSF1 is 
subsequently unfolded via a heat-mediated mechanism [48, 49]. HSF1 then undergoes 
trimerization [49, 50], nuclear localization, and phosphorylation [51–53] in order to promote 
transcription of target genes. In this classical heat shock response mechanism, many HSF 1 
targets are HSPs that further aid in protecting the proteome and aiding cell survival.
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3. ROLE OF HSF1 IN TUMOR PROGRESSION
HSF1 appears to have many functions that promote tumorigenesis and tumor progression 
(Fig. 2). The first discovery of HSF1 playing a role in cancer was in prostate cancer cells [8]. 
Since that time, the number of publications related to HSF1 and cancer has steadily 
increased to greater than 50 publications per year since 2015. These discoveries span the 
breadth of tumor biology. This review will focus on the role of HSF 1 in metastasis, cell 
proliferation and apoptosis, and tumor metabolism as these areas are relevant to HSF1 as a 
biomarker and potential therapeutic target.
3.1. Migration, Invasion, and Metastasis
The first discovery of HSF1 playing a role in cancer in prostate cancer cells showed that 
HSF1 had higher expression in a metastatic variant of PC-3 cells [8], suggesting that it may 
be altered in metastatic cancer cells. We observed a similar outcome with increased HSF1 
activation in breast cancer metastatic variant cell lines compared to the parental non-
metastatic cells [54]. Our data indicated that HSF1 activity is strongly associated with 
metastasis in a large cohort of breast cancer patients [54]. In addition, HSF1 expression or 
activity is increased in advanced stage tumors from multiple sites [8, 17, 24, 27] suggesting 
that HSF1 drives tumor progression toward metastasis. One clear piece of evidence that 
HSF1 plays a role in tumorigenesis and metastasis is deletion of HSF1 in the MMTV-Neu 
mouse model resulted in decreased breast tumor formation and lung metastasis [55]. 
Similarly, HSF1 overexpression increased metastasis in a hepatocellular carcinoma mouse 
model whereas HSF1 knockdown reduced metastasis [17]. These data indicate that HSF 1 is 
strongly associated with and necessary for metastasis.
Several studies indicated that HSF1 can drive migration, invasion, and anchorage-
independent growth of cancer cells. For example, deletion of HSF1 from mouse embryonic 
fibroblasts reduces their anchorage-independent growth [56] and migration [57] suggesting 
that HSF 1 is critical for these functions at a basal level. Several studies have shown similar 
results that migration and invasion are reduced with loss of HSF1 using cancer cells from 
osteosarcoma [35], ovarian cancer [31], melanoma [24, 58], pancreatic cancer [27], 
hepatocellular carcinoma [17], breast cancer [59], and lung cancer [60]. These 
characteristics are key features of epithelial-to-mesenchymal transition (EMT). We and 
others have shown that HsF1 promotes EMT [31, 55, 60, 61]. Not only has our lab and 
others shown HSF1 expression promotes EMT-like changes, it also appears that HSF1 is 
required for TGFβ-induced EMT as well [31, 55], possibly suggesting that HSF 1 is critical 
to the core process of EMT rather than just one of many molecules that can initiate EMT.
There are several proposed mechanisms by which HSF1 promotes EMT-like phenotypes and 
metastasis. Our data indicate that HSF1 can bind and upregulate Slug, an EMT-promoting 
transcriptional repressor [61]. However, considering the lessened importance of Slug in 
EMT of breast cancer cells [62], it is likely HSF1 also utilizes additional mechanisms. For 
instance, HSF1 has been shown to upregulate β-catenin via HuR [63] and loss of HSF1 
reduced NFκB activation and suppressed tumor growth [16]. HSF1 activation in hepatoma 
cells led to HSF1-driven Cln-1 expression leading to cell invasion [64]. Loss of HSF1 in a 
lung tumor model also showed a decrease in migration associated with a decrease in 
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vinculin, an actin-binding protein known to promote cell migration [60]. HSF1 has been 
shown to regulate miRNAs such as upregulation of miR-135b, leading to upregulation of 
MMP2/9 and changing actin dynamics to allow for migration and invasion [65]. HSF1 has 
also been shown to interact with and cooperatively regulate gene expression with metastasis-
associated protein 1 (MTA1) [66]. In addition, HSF1 promotes aneuploidy [67, 68], another 
mechanism associated with tumor progression.
A broader look at the mechanism by which HSF1 sustains tumor growth and malignancy 
was addressed by ChIP-Seq for HSF1 in tumors [12]. Interestingly, it was observed that 
HSF1 -bound genes in cancer were unique from HSF1 -bound genes during heat shock [12]. 
Despite a seemingly ubiquitous mechanism of HSF1 activation via trimerization and S326 
phosphorylation, as well as having a similar binding sequence, the genes HSF1 regulated 
were unique in these two contexts. The genes involved in the cancer-specific HSF1 program 
involved genes from many aspects of tumor biology including energy metabolism, apoptosis, 
transcription, translation, and extracellular matrix [12]. Despite having a cancer-specific 
transcriptional program, HSF1 also has the capability to promote malignancy via its role as a 
stress-response protein. MEK-induced HSF1 activity has been shown to suppress apoptosis 
induced by the unfolded protein response in cancer cells [69]. Preventing HSF1-induced 
activity in response to accumulation of unfolded proteins suppressed metastasis [69]. As 
such, HSF1 utilizes multiple mechanisms to support tumor growth and progression toward 
metastasis.
Another potential mechanism for HSF1 to promote tumorigenesis and metastasis is 
enhancing the cancer stem cell population. We and others have shown increased HSF1 
activation or expression in the cancer stem cell population [54, 63, 70]. We also showed that 
HSF1 expression enhanced spheroid formation in breast cancer cells and that inhibition of 
HSF1 reduced sphere formation and the cancer stem cell population [54]. Similarly, HSF1 
knockdown also reduced spheroid formation [54, 70]. In accordance with increased HSF 1 
activity in cancer stem cells, expression of Hsp27 and Hsp90 have also been linked to 
stemness [32, 71].
3.2. Cell Proliferation and Viability
Aside from being involved in several different areas of tumor biology, HSF1 also seems to 
be involved in regulating cell proliferation and turnover, a central aspect of tumor formation 
and growth. HSF1-null MEFs have lower proliferation rates and often showed incomplete 
mitosis compared to WT MEFs, suggesting that HSF1 has some impact on cell proliferation 
[11, 72]. Interestingly, HSF1 is directly involved in the cell cycle as it is phosphorylated at 
S216 leading to degradation during mitosis and mitosis is interrupted without this event [72]. 
HSF1 expression has also been seen to increase CyclinD levels and suppress p21 and p27 
[59, 73]. While HSF1 is known to promote expression of genes that leads to enhanced cell 
proliferation and survival, it also seems to have a direct influence on the cell cycle.
The classical function of HSF1 is to respond to a cell stress in an effort to promote cell 
survival. Consistent with this function, HSF 1 induces several mechanisms to suppress 
apoptosis and cell death. HSF1-null MEFs showed higher rates of apoptosis compared to 
WT MEFs suggesting the lack of HSF1 predisposed cells to apoptosis [11]. HSF1 activation 
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has been linked to the upregulation of several anti-apoptotic proteins including Bcl-xL, 
Mcl-1, Bcl-2, and survivin [59, 74–76]. The enhanced expression of these anti-apoptotic 
proteins has been shown to be mediated by HSF 1 -induced expression of chaperones 
including Hsp27 and BAG3 [59, 75, 76]. In addition to an increase in anti-apoptotic proteins, 
HSF1 also promotes the suppression of XAF1, an endogenous suppressor of XIAP, 
ultimately leading to suppression of apoptosis [77]. Furthermore, HSF1 activity suppresses 
expression of SMAC, an integral protein in the mitochondrial pathway of apoptosis [28].
Another interesting mechanism of cell survival promoted by HSF1 is autophagy. HSF1 was 
first shown to upregulate ATG7 leading to cell autophagy and desensitization to 
chemotherapy [78]. HSF1 was later shown to coregulate ATG7 with PSMD10 to induce 
autophagy and also promote resistance to sorafenib [79]. In its role as a stress response gene, 
HSF1 also upregulates RIPK1 in response to ER stress to promote autophagy and cell 
survival [80]. In addition to regulating ATG7, HSF1 was recently shown to upregulate 
ATG4B to promote cell-protective autophagy in response to epirubicin [81]. Thus, this is an 
alternative mechanism by which HSF1 seems to promote cell survival in response to cancer 
treatments.
3.3. Cancer Cell Metabolism
Cancer cells have a characteristic change in metabolic flux toward glycolysis known as the 
Warburg effect [82]. Interestingly, HSF1 seems to push cells toward the Warburg effect. 
Inhibition of HSF1 activity results in decreased lactate and glucose uptake suggesting that 
HSF1 supports these metabolic changes characteristic of tumor cells [83]. Furthermore, 
HSF1-null mouse embryonic fibroblasts (MEFs) has less glucose uptake and less tolerance 
to low glucose conditions compared to wild-type MEFs indicating that the presence of HSF1 
may promote a higher dependence on glycolysis [11]. One consequence of increased flux 
through glycolysis is increased lactate production and HSF1 has been shown to upregulate 
lactate dehydrogenase (LDH) and loss of HSF1 reduces LDH levels [84, 85].
HSF 1 has interaction with several proteins that influence tumor cell metabolism. For 
instance, glucose-mediated activation of mTOR leads to HSF1 activation [86]. HSF1 is 
negatively regulated by AMPK and PGC-1α [27, 87, 88]. AMPK acts as a tumor suppressor 
and is a cellular metabolic stress sensor and maintains cellular energy homeostasis by 
detecting changes in AMP/ATP levels. AMPK can interact with HSF1 and phosphorylate 
S121 leading to suppression of HSF1 activity [27, 87]. Loss of AMPK resulted in enhanced 
HSF 1 activity and metastasis of pancreatic cancer cells [27]. PGC1-α is a metabolic 
transcriptional coactivator that enhances oxidative metabolism and mitochondrial biogenesis 
[89]. PGC1-α has been shown to directly interact with HSF1 on DNA and suppress 
expression of heat shock response-related HSF1 target genes as well as non-heat-related 
HSF1 target genes [88]. Though more work is needed to clearly understand mechanisms, 
HSF1 clearly has an impact on tumor cell metabolism.
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4. HSF1 AS A POTENTIAL BIOMARKER AND THERAPEUTIC TARGET
4.1. HSF1 as a Cancer Biomarker
Elevated levels of HSF1 are generally associated with poor prognosis (Table 1). A genome-
wide search for target sites of HSF 1 in breast cancer cell lines with different metastatic 
capacities was undertaken by comparing cells with high and low malignant potential 
alongside their non-transformed counterparts [12]. Investigators identified an HSF1-
regulated transcriptional program specific to highly malignant cells and distinct from heat 
shock [12]. They could further document this program was active in other cancers such as 
colon and lung and that it contributed to the metastases and death of patients [12]. A number 
of clinical studies have now also documented the role of HSF1 in human cancers. These 
include breast cancer, colon cancer, lung cancer, endometrial cancer, hepatocellular 
carcinoma, oral squamous cell carcinoma and prostate cancer [90].
Breast and colon cancer illustrate well the nuances of the role of HSF1 in human cancers. 
Santagata et al. analyzed breast cancer samples from 1,841 participants enrolled in the 
Nurses’ Health Study by immunohistochemistry and correlated the expression with clinical 
parameters and survival outcomes [13]. Nuclear HSF1 levels were elevated in ~80% of in 
situ and invasive breast carcinomas. In invasive carcinomas, high HSF 1 expression was 
associated with high histologic grade, larger tumor size, and nodal involvement at diagnosis. 
Furthermore, high HSF1 levels were found to be independently associated with increased 
mortality, particularly in ER+ patients. Our group analyzed the TCGA cohort of 
approximately more than 1,000 women for the presence of mutations; these were not 
common (~0.2%) [42]. Copy number alterations were more common (14.8%) with almost 
all of these being amplification events. However, these were not associated with prognosis in 
all breast cancer subtypes. We further analyzed the RNA expression of HSF1 in a well 
annotated publically available dataset (GOBO) of breast cancer patients. In this analysis, we 
were able to document that high levels of HSF 1 mRNA were associated with poor overall 
and relapse free survival in all breast cancer patients. This was also true in a subset analysis 
of ER-negative (p=0.005) and in ER-positive patients (P=0.00045). There was a significant 
correlation with outcomes in those with or without endocrine therapy among ER+ patients 
[42]. Together, these studies document the importance of HSF1 in patients with breast 
cancer using immunohistochemistry as well as mRNA expression analysis.
Based on initial work in breast cancer, a gene expression signature consisting of 456 genes 
was termed an HSF1-cancer signature [12]. This signature not only identified patients with 
poor prognosis in breast cancer cohorts, but also identified patients with colon and lung 
cancer with poor outcomes. This is consistent with prior work that documented the 
importance of this pathway in colon cancer in a comparative analysis of normal and sporadic 
colon cancers (n=35) [9].
Outside of breast and colon cancer, HSF 1 also seems to serve as a prognostic biomarker in 
other tumor types. HSF 1 has increased expression in hepatocellular carcinoma (HCC) and 
high expression was associated with overall survival as well as metastasis-free survival of 
HCC patients [17]. This association was independent of cirrhosis status, tumor size, the 
number of tumor nodules, capsular formation, tumor grade, and venous invasion [17]. HSF1 
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expression levels were a significant predictor of endometrial cancer survival with higher 
levels of HSF 1 predictive of poor prognosis in both ER+ and ER- patients [30]. High 
expression levels of HSF1 was also a strong predictor for poor overall survival and 
recurrence-free survival of pancreatic cancer and melanoma [24, 28]. High HSF1 expression 
in esophageal carcinomas, or expression in the neighboring stromal cells of these tumors, 
was highly predictive of overall survival and disease-free survival [23, 91]. High HSF1 
levels were also associated with poor survival in osteosarcoma patients [35]. These data 
were recently summarized in a meta-analysis including over 3,000 patients that concluded 
high HSF1 expression was significantly associated with overall survival or recurrence-free 
survival in all tumor types tested [90]. High HSF1 was additionally associated with many 
phenotypes of tumor progression such as tumor staging and tumor grade among others [90]. 
Another potential marker for HSF1 activity is the levels of phosphorylated HSF1 as this is 
required for transcriptional activity [51]. Specifically, phosphorylation at Ser326 is 
important for transcriptional activity and levels of HSF1 phospho-Ser326 have been shown 
to be predictive for overall survival in ovarian cancer [32].
The potential for HSF1 as a biomarker will require greater understanding of the basic 
biology of HSF1 in conditions of heat shock and cancer. Levels of HSF1 mRNA and protein 
have both been shown to be predictive for patient outcomes in multiple tumor types (Table 
1). It is a generally held view that HSF1 is constitutively expressed in cells but requires 
activation for transcriptional activity. However, HSF1 has been shown to be amplified in 
breast cancer in 1015% of cases [10, 42]. However, the prognostic impact in breast cancer is 
specific to mRNA expression, but stayed insignificant by protein expression or by analyzing 
amplification events. Other studies suggest nuclear HSF 1 levels are important for HSF 1 
activity and a predictor for patient outcome [12, 13, 24]. However, early studies on HSF1 
suggested the protein is localized to the nucleus and DNA binding can occur independent of 
heat stress or phosphorylation [92–94]. As such, a full understanding of the steps for HSF1 
activation will help considerably to choose which aspect of HSF 1 to use as a biomarker.
4.2. HSF1 as a Therapeutic Target
Therapeutic targeting of transcription factors has previously had mixed results. However, 
considering the importance of transcription factors in tumorigenesis and tumor progression, 
targeting transcription factors has become more accepted. Targeting HSF1 has remained in 
the pre-clinical stage of testing due to the lack of an efficacious and specific drug to inhibit 
HSF1 transcriptional activity.
Independent of attempts to develop an HSF 1 -specific inhibitor, several studies have shown 
successful repression of cancer cell growth with depletion of the HSF 1 gene. Loss of HSF1 
activity by expression of a dominant negative suppressed aneuploidy and proliferation of 
prostate carcinoma cells as well as the proliferation of melanoma cells [25, 69, 95]. 
Knockdown of HSF1 also reduced the proliferation and xenograft tumor size of ovarian, 
glioblastoma, and pancreatic tumors [27, 28, 96]. Genetic ablation of HSF1 in p53-deficient 
mice suppressed lymphoma tumor incidence and enhanced tumor-free survival [15]. 
Similarly in breast cancer, heterozygous or homozygous deletion of HSF1 reduced tumor-
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free survival and incidence of metastasis in MMTV-neu mice [55]. Thus, reduction in HSF1 
levels and/or activity is suppressive to cancer cell growth and tumor size.
There have been multiple attempts to develop a targeted inhibitor of HSF1 activity. KNK437 
is a compound that was found to suppress expression of heat shock proteins and thermo-
tolerance [97]. KNK437 has shown activity in suppressing tumorigenic properties of cancer 
cells, including suppressing cancer stem cell phenotypes, but these effects have primarily 
been observed in the role of enhancing the toxicity of other anti-tumorigenic compounds 
such as radiation, gemcitabine, or bortezomib [98–100]. KNK423, a metabolite of KNK437, 
also seemed to have inhibition of HSF1 [101]. However, both KNK437 and KNK423 have 
shown off-target effects indicating its specificity to HSF1 is limited [83, 102]. Another 
compound was discovered from a 2009 screening of a small 1300 compound library that was 
named “Compound 1” and was found to inhibit HSF1 activity but information on the 
compound itself is not currently in the public domain [103]. Another screening of >6,000 
compounds from the Korea Chemical Bank identified KRIBB11 as having a suppressive 
effect on HSF1 activity, primarily via interaction with the transactivation domain preventing 
the recruitment of pTEFb and transcriptional elongation [104]. This compound has shown 
both in vitro suppression of cancer cell growth and in vivo suppression of tumor growth 
from our lab and others [54, 105, 106]. Although this compound was seemingly highly 
specific to HSF 1 because it directly interacts with HSF1, it appears to possibly have an off 
target effect on Mcl-1 [106]. A triazole nucleoside, Ly101–4b, was found to have a 
suppressive effect on HSF1 protein level and the subsequent expression of heat shock 
proteins and HSF1-regulated miR-214 [107, 108]. While the precise mechanism by which 
Ly101–4b suppresses HSF1 expression is unclear, the anti-tumor effect of Ly101–4b is 
potent in preclinical models of pancreatic cancer [107, 109]. Rohinitib (RHT), an analog of 
the natural compound rocaglamide A, was shown to suppress HSF1 activity [83]. This RHT 
compound was effective at reducing growth of several solid and hematopoietic tumor lines 
in vitro and in vivo with evidence of reduced HSF1 activity [83]. Subsequent modeling of 
RHT showed it had significant interaction with the DNA binding domain of HSF1 [110]. 
Another compound, named PW3405 from the Prestwick chemical library, was found to 
inhibit HSF1 phosphorylation and activity [111]. PW3405 was a potent inhibitor of cancer 
cell viability with a broad range of tumor types in vitro with the IC50 in the submicromolar 
range for all cell lines tested [111]. Considering the importance of HSF1 phosphorylation to 
its activity [51], it is possible PW3405 is inhibiting kinases upstream of HSF 1 reducing its 
phosphorylation and activity although this possibility has not been investigated. A chemical 
compound, CCT251236, was identified via an HSF1 phenotypic screen to suppress HSF1 
activity measured by induction of Hsp72 [112]. This compound strongly suppressed HSF1 
activity at low doses and suppressed subcutaneous xenograft tumor growth with ovarian 
cancer cells [112]. However, it was also found that this compound was directly interacting 
with pirin rather than targeting HSF1 [112]. Recently, IHSF115 was developed to inhibit 
HSF1 using modeling of the DNA binding domain of HSF1 and was shown to directly bind 
HSF1 and suppress its activity [113]. Despite predictive modeling suggesting IHSF115 would 
bind the DNA binding domain, it did not affect HSF 1 binding to target genes but likely 
suppressed HSF1-induced recruitment of transcriptional machinery [113]. This compound 
was able to suppress the growth of a number of cancer cell lines although the dosages 
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needed were all in the micromolar range [113]. An alternative approach to inhibit HSF1 
activity was developed through an RNA aptamer that suppresses HSF1 activity in both heat 
shock and cancer contexts by preventing the binding of HSF1 to target genes using a 
sequence specific to the DNA binding domain [114–117]. This strategy was sufficient to 
suppress the growth of cancer cells and suppress expression of HSF1 target genes using a 
plasmid-based delivery system [114]. The utility of such a system for suppressing tumor 
growth in vivo is unknown.
In addition to targeted small molecules directed at HSF1, there are also natural compounds 
known to suppress HSF1 activity. Quercetin, a plant polyphenol from the flavonoid group, 
was identified to inhibit the heat shock response by down regulation of HSF1 [118]. Being a 
natural compound, quercetin also seems to inhibit multiple targets and, therefore, is not 
specific to HSF1 [83]. Triptolide, a natural compound derived from tripterygium wilfordii 
was also discovered to suppress HSF1 activity by interfering with the HSF1 transactivation 
domain [119]. It has subsequently been shown to have several anticancer properties but also 
other cellular targets, indicating it lacks specificity to HSF1 [83, 120]. The natural 
compound rocaglamide A was found to have selective HSF1 inhibition by preventing HSF1 
binding to target genes [83]. Analogs to this compound, in particular RHT, was found to 
have more specific and potent effects [83].
CONCLUSION
The role of HSF1 in cancer has become a highly discussed topic in the last decade. As recent 
as 2005, there were only 5 published papers indexed in MEDLINE that included HSF 1 and 
cancer whereas there were more than 50 published papers on HSF1 and cancer in 2,017. It 
has become clear that HSF 1 functions in its role as the regulator of the heat shock response 
in cancer cells considering that heat shock proteins themselves play a role in tumorigenesis. 
But it is also clear that HSF 1 has a cancer-specific transcriptional program that supports 
malignancy [12]. Our lab and others have shown HSF 1 to play a role in the migratory and 
invasive capability of cancer cells as well as metastasis. Beyond this, HSF1 appears to have a 
pleiotropic effect on malignancy as it has been shown to play a role in many aspects of 
tumor biology from DNA repair [121] to angiogenesis [122] to metabolism [83]. All of these 
functions of HSF1 appear to support the malignancy of cancer cells and, therefore, makes 
HSF1 a possible biomarker for tumors that are progressing toward metastasis. HSF1 has 
been shown to be a strong predictor of patient outcomes in multiple cancer types, especially 
breast and colon cancers. However, further development of HSF 1 as a biomarker is 
necessary as studies are not consistent with their evaluation of HSF1. For example, some 
studies have used raw HSF 1 expression as a marker, whereas others have used nuclear 
HSF1 or phosphorylated HSF1 at Ser326. A clear understanding of which of these markers 
most accurately reflect HSF1 activity will be helpful to understand mechanistically how 
these different detections of HSF1 contribute to tumor progression. Because HSF 1 supports 
tumor progression and could possibly serve as a biomarker, there have also been attempts to 
target HSF1 therapeutically. These agents have yet to make it to the clinic likely because 
many of them have obvious off-target effects and are not highly specific to HSF 1. 
Continued development of HSF 1 inhibitors in preclinical in vivo models with biomarkers 
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for response to these treatments will be necessary prior to any attempt in human trials is 
possible.
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Fig. (1). 
Heat Shock Factor 1 (HSF1) Gene. A) There are six human HSF isoforms all containing a 
homologous DNA binding domain recognizing the heat shock element (HSE). B) HSF1 is 
located on the long arm of chromosome 8 at q24.3. The resulting gene has 13 exons with a 
full gene size of 23,135 bp that transcribes to an mRNA of 2,193 bp. The resulting protein is 
529 aa and has multiple functional domains. The DNA binding domain (DBD) is a winged 
helix-turn-helix domain. The leucine zipper (LZ) domains mediate the trimerization of 
HSF1 upon activation. The regulatory domain is home to many post-translational 
modifications that appear to regulate HSF1 transcriptional activity with Ser326 seemingly 
the key phosphorylation necessary for activity. The transactivation domain (TAD) of HSF1 
recruits p-TEFb to release proximal promoter pausing and promote transcription elongation 
of target genes.
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Fig. (2). 
HSF1 Function in Tumorigenesis and Tumor Progression. HSF1 has been shown to be 
phosphorylated and activated at Ser326 by AKT1 [61], MEK [69], p38 [123], and mTOR 
[124]. HSF1 directly regulates multiple genes to promote migration, invasion, and EMT that 
ultimately translates to tumor progression and metastasis. HSF1 also appears to directly 
upregulate and downregulate several genes that lead to enhanced cell proliferation and 
survival. In addition, HSF1 has direct effects on genes that promote the Warburg effect of 
increasing glycolysis in cancer cells. Together these functions, and others, suggest HSF1 has 
multiple effects that lead to tumorigenesis and tumor progression.
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